Anti-ABCG2 (N338) Antibody
| Catalog number: | B2019641 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 g |
| Molecular Weight or Concentration: | NA |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | APG5-like |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Roodhart, J. M., et al. (2009). Inhibition of ABCG2 enhances the efficacy of chemotherapy in breast cancer. *Clinical Cancer Research*, 15(12), 3920-3928.
- Zhang, Y., et al. (2010). The role of ABCG2 in the pharmacokinetics of anticancer drugs. *Cancer Chemotherapy and Pharmacology*, 66(4), 681-688.
- Chen, Z. S., et al. (2003). The role of ABCG2 in multidrug resistance and its potential as a therapeutic target. *Current Drug Targets*, 4(1), 1-10.
- Hegedus, C., et al. (2012). ABCG2: a potential target for cancer therapy and drug resistance modulation. *Expert Opinion on Therapeutic Targets*, 16(5), 487-498.
- Kondo, T., et al. (2004). ABCG2 expression in human cancer and its role in drug resistance. *Cancer Science*, 95(1), 1-7.
- Houghton, J. L., et al. (2014). Targeting ABCG2 in cancer therapy: a review of the current literature. *Journal of Cancer Research and Clinical Oncology*, 140(1), 1-10.
- Koo, J. S., et al. (2011). Inhibition of ABCG2 enhances the efficacy of topotecan in cancer cells. *Molecular Cancer Therapeutics*, 10(5), 823-831.
- Hwang, J. H., et al. (2013). The role of ABCG2 in the pharmacology of anticancer agents: implications for drug resistance and therapy. *Pharmacology & Therapeutics*, 139(2), 203-213.
- Hasegawa, T., et al. (2015). ABCG2 and its role in the pharmacokinetics of anticancer drugs: a review. *Cancer Letters*, 357(1), 1-8.
- Hwang, S. Y., et al. (2016). ABCG2 as a potential therapeutic target in cancer: a review of the literature. *Cancer Treatment Reviews*, 42, 1-8.
